ArticleJHLT open2025
Living myocardial slices retain patient-specific features: Insights into etiology and therapeutic history.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Living Myocardial Slice Technology for Heart Failure Research.Current heart failure reports · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Living myocardial slices (LMS) are an emerging translational Methods: 300-µm-thick LMS were prepared from myocardial biopsies of end-stage heart failure patients ( Results: LMS exhibited lower intrapatient variability (LMS from the same patient) compared to interpatient variability (LMS from different patients), confirming their ability to retain patient-specific functional properties. LMS from LVAD-treated patients exhibited reduced intrapatient variability and reduced diastolic tension, correlated with lower N-terminal pro-B-type natriuretic peptide levels. Stratification by etiology revealed distinct functional characteristics, including enhanced contractile force in titin-mutant LMS and a positive force-frequency relationship in ischemic cardiomyopathy-derived LMS. LMS derived from amiodarone-treated patients demonstrated prolonged action potential duration, reduced excitability at higher pacing frequencies, and enhanced post pause potentiation, reflecting the drug's established pharmacological effects. Conclusions: LMS effectively capture distinct functional parameters associated with patient-specific features. These findings establish LMS as a valuable translational platform for personalized cardiac research, therapeutic testing, and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.